🔎 Trials Near Me

ホーム › 胆道系癌

米国で参加者を募集している胆道系癌の臨床試験

米国全土の拠点で、胆道系癌に関する40件の研究が参加者を募集しています。

最も多くの研究がある都市

州別

最近更新された研究

公式研究テキスト（英語）

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

被験者募集中観察研究
2歳〜100歳 · 全性別 · 2026/10/02更新 · NCT01950572

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06219941

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07265674

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05482893

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07221253

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06428409

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT05523947

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

被験者募集中第2相
18歳〜130歳 · 全性別 · 2026/09/23更新 · NCT05489211

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

被験者募集中第2相
19歳以上 · 全性別 · 2026/09/22更新 · NCT07146646

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06282575

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT07812805

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06548412

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/09/04更新 · NCT07038343

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

被験者募集中第1相
18歳以上 · 全性別 · 2026/08/24更新 · NCT06084481

Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

被験者募集中観察研究健康なボランティア歓迎
18歳〜99歳 · 全性別 · 2026/08/24更新 · NCT05517811

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06774963

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/08/19更新 · NCT06467357

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

被験者募集中第3相
18歳以上 · 全性別 · 2026/07/30更新 · NCT06622057

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

被験者募集中
18歳以上 · 全性別 · 2026/07/02更新 · NCT06101277

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

被験者募集中第1相
18歳以上 · 全性別 · 2026/06/29更新 · NCT07458347

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。